![Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Research and Practice in Thrombosis and Haemostasis Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Research and Practice in Thrombosis and Haemostasis](https://www.rpthjournal.org/cms/attachment/cc6048e5-cd67-4b87-9c7c-2a0dc04292b5/rth212614-fig-0001-m_lrg.jpg)
Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Research and Practice in Thrombosis and Haemostasis
![Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Speed - 2021 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Speed - 2021 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cfd91597-dd2d-4310-8267-896c5b5de32c/rth2.v5.8.cover.jpg?trick=1693437682371)
Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry - Speed - 2021 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
![PDF) The implementation of Systems-Theoretic Accident Model and Processes on standardization of safety in mechatronic systems (humanoids) PDF) The implementation of Systems-Theoretic Accident Model and Processes on standardization of safety in mechatronic systems (humanoids)](https://i1.rgstatic.net/publication/261361680_The_implementation_of_Systems-Theoretic_Accident_Model_and_Processes_on_standardization_of_safety_in_mechatronic_systems_humanoids/links/59a81a77aca272d1b84aebb8/largepreview.png)
PDF) The implementation of Systems-Theoretic Accident Model and Processes on standardization of safety in mechatronic systems (humanoids)
![Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants | Open Heart Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants | Open Heart](https://openheart.bmj.com/content/openhrt/5/1/e000788/F1.large.jpg)
Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants | Open Heart
![PDF) Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants PDF) Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants](https://i1.rgstatic.net/publication/324677812_Strengths_and_weaknesses_of_'real-world'_studies_involving_non-vitamin_K_antagonist_oral_anticoagulants/links/5adb2cdf458515c60f5ce98f/largepreview.png)
PDF) Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants
![PDF) COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: A non-interventional study PDF) COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: A non-interventional study](https://i1.rgstatic.net/publication/327425000_COSIMO_-_patients_with_active_cancer_changing_to_rivaroxaban_for_the_treatment_and_prevention_of_recurrent_venous_thromboembolism_A_non-interventional_study/links/5b8eba3492851c6b7ebf4650/largepreview.png)
PDF) COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: A non-interventional study
![ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months - ScienceDirect ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0049384820305053-gr1.jpg)
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months - ScienceDirect
![COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study | Thrombosis Journal | Full Text COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study | Thrombosis Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12959-018-0176-2/MediaObjects/12959_2018_176_Fig1_HTML.png)